Latest news with #LagunaHills
Yahoo
03-07-2025
- Health
- Yahoo
The Number-1 Food to Help Reduce Your Risk of Stroke, According to Dietitians
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." About 795,000 people in the U.S. experience a stroke each year, which can be a life-altering experience. While you can't influence some risk factors like your age or your genetics, there are lifestyle tweaks you can make to help. That includes making diet tweaks by adding foods that may help lower your risk of stroke. Overall, following a healthy eating pattern can help lower a slew of stroke risk factors, including your blood pressure, cholesterol, and blood sugar regulation, says Cheng-Han Chen, M.D., interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA. Meet the experts: Scott Keatley, R.D., co-owner of Keatley Medical Nutrition Therapy; Keri Gans, R.D.N., dietitian and host of The Keri Report podcast; Sonya Angelone, R.D.N., is a nutritionist and registered dietitian based in San Francisco, California; Kristine Dilley, R.D.N, a nutritionist at The Ohio State University Wexner Medical Center; Cheng-Han Chen, M.D., interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA There are specific diets linked to a lower risk of stroke: the DASH diet and Mediterranean diet. 'These dietary patterns are similar in that they both encourage increasing your intake of plant-based foods such as vegetables, fruits, whole grains, beans and legumes; lean meats, fish, low-fat dairy, and heart healthy fats such as olive oil,' says Kristine Dilley, R.D.N, a nutritionist at The Ohio State University Wexner Medical Center. 'In addition to the nutritional benefits of these diets, they are also generally lower in calorie density which may aid in weight loss. Even relatively small decreases in weight can significantly improve your risk.' Certain nutrients may be more helpful than others, though. 'Diets rich in anti-inflammatory [foods] and nutrients that keep your veins and vessels nice and open—like potassium, omega-3s, polyphenols, and magnesium—can lower blood pressure, improve artery flexibility, and reduce clotting, all of which significantly reduce the risk of both ischemic and hemorrhagic strokes,' says Scott Keatley, R.D., co-owner of Keatley Medical Nutrition Therapy. It's also important to limit certain things if you're worried about your stroke risk. 'Having a balanced diet lower in saturated fat, lower in sugar, and lower in processed foods will all be helpful,' Dr. Chen says. While focusing on an overall healthy diet is important, it's fair to wonder if certain foods are better for reducing your stroke risk than others. With that in mind, these are the biggest foods dietitians and a cardiologist recommend focusing on to lower your stroke risk. While Dr. Chen says you can't go wrong focusing on fruits, vegetables, nuts, whole grains, and lean proteins, some foods may be more powerful for lowering your risk of stroke than others. These are the biggies, according to experts. Think: Spinach, kale, and arugula. These are a top choice of Sonya Angelone, R.D.N., a nutritionist and registered dietitian based in San Francisco, California. 'Green leafy vegetables can lower stroke risk because of their high content of nitrates,' she says. 'The body converts nitrates into nitric oxide, which can help relax the pressure in arteries, promote healthy blood flow, and reduce blood pressure.' A study published in the European Journal of Epidemiology in 2021 found a link between people who had at least 60 milligrams a day of nitrates from vegetables and a 17% lower risk of stroke. (That's equal to about a cup of leafy green vegetables.) Leafy greens are also rich in vitamin K, which helps regulate clotting, Keatley says. 'They also have vitamins, minerals, and fiber which are associated with a lower stroke risk,' Angelone says. Citrus fruits like oranges and grapefruit contain vitamin C, folate, and potassium, which have antioxidant and anti-inflammatory properties, Dilley says. These also contain soluble fiber, which can help lower your cholesterol (another stroke risk factor). Just be aware that grapefruit can interfere with certain medications, so Angelone warns that it's best to check in with your healthcare provider to make sure you're not taking anything that may interact with the fruit. Walnuts have repeatedly been flagged as a food that's friendly to your cardiovascular system. One study published in the journal Circulation in 2021found that eating about a ½ cup a day of walnuts for two years lowered levels of LDL ('bad') cholesterol. (High levels of LDL cholesterol are a risk factor for stroke.) The big allure of walnuts is their omega-3 fatty acid content. 'This may support heart health and reduce inflammation in the body,' says Keri Gans, R.D.N., dietitian and host of The Keri Report podcast. 'They are a good source of alpha linolenic acid, a type of omega-3 fatty acid,' Angelone says. 'This has been shown to reduce inflammation, improve blood flow, and lower blood pressure.' Walnuts are also packed with antioxidants and other nutrients that are protective for your cardiovascular system, she says. 'Yogurt offers calcium, potassium, and probiotics, which contribute to lower blood pressure and better lipid balance, particularly when it replaces processed or sugary snacks,' Keatley says. Something else to consider, per Angelone: Yogurt is considered part of the DASH diet, which is also great for stroke prevention. Just aim for low-sugar options, since Dr. Chen points out that added sugar can raise your risk of cardiovascular disease. Whole grains like oats are packed with magnesium, B-vitamins, and antioxidants to protect your vascular health, Keatley says. 'They also contribute fiber that promotes steady blood sugar,' he says. Whole grains may also help tamp down on bodily inflammation, further lowering your stroke risk, Angelone says. Fatty fish like salmon, sardines, and mackerel are rich in EPA and DHA, Keatley points out. 'These reduce inflammation, stabilize heart rhythm, improve lipid profiles, and make platelets less sticky, thus reducing clot risk,' he says. Fatty fish can also help to lower your blood pressure and cholesterol, which are major risk factors for stroke, Angelone says. One more thing to consider, per Dilley: Fatty fish are a lean source of protein, which can help with weight management, and excess weight is linked with a higher risk of stroke. Soluble fiber retains water and turns into a gel in your GI tract, slowing digestion. Foods rich in soluble fiber lower LDL cholesterol and help manage blood sugar spikes that can damage your blood vessels, Keatley says. There are a bunch of foods that fall into this category, but Dilley says these are some of the best: Apples Apricots Figs Pears Carrots Broccoli Sweet potatoes While Dr. Chen recommends that his patients have lean proteins, he says he specifically encourages plant-based proteins. Research published in The American Journal of Clinical Nutrition in 2024 found that, compared to people who ate high levels of animal protein, people who ate plant-based protein had a 19% lower risk of cardiovascular disease and a 27% lower risk of coronary heart disease. 'Beans such as black beans and kidney beans are a nutritional powerhouse in that they supply both soluble fiber and a healthy serving of plant-based protein at meals,' Dilley says. 'Increasing intake of plant-based proteins allows you to decrease intake of some animal-based foods that may be higher in saturated fat.' The foods we just mentioned are the biggest ones flagged by dietitians and Dr. Chen, but experts say these are also worth adding to your dietary rotation: Coffee. 'The chemical compounds in coffee, including trace minerals and phenolic compounds, act as antioxidants and may have a beneficial effect on cholesterol levels, oxidation, and inflammation,' Angelone says. 'So, drinking moderate amounts of coffee, including decaf, may help decrease risk for stroke.' Beets. 'These are also nitrate-rich and support nitric oxide production,' Keatley says. Avocados. These fruits 'provide potassium and heart-healthy monounsaturated fats,' according to Keatley. Green tea. Rich in catechins that reduce oxidative stress, sipping green tea may help lower your stroke risk, Keatley says. Legumes. These powerhouse plants 'supply plant-based protein and fiber,' Keatley points out. Dark chocolate. The flavonoids found in dark chocolate 'improve nitric oxide bioavailability and may modestly reduce blood pressure,' Keatley says. (Just eat this in moderation, of course.) If you're especially concerned with your stroke risk, Dr. Chen says it's important to talk to a healthcare provider. They can walk you through your personal risk factors, as well as what you can do to lower your risk. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
New York Times
20-06-2025
- Entertainment
- New York Times
Terry Louise Fisher, a Creator of ‘L.A. Law,' Dies at 79
Terry Louise Fisher, who channeled her experience as a Los Angeles prosecutor into an Emmy Award-winning television career as a writer and producer for 'Cagney & Lacey,' the groundbreaking female-oriented police procedural, and a creator, with Steven Bochco, of the sleek drama 'L.A. Law,' died on June 10 in Laguna Hills, Calif. She was 79. Her death was confirmed in a social media post by Mark Zev Hochberg, a family member. He did not cite a cause. Ms. Fisher was best known for her work on shows about cops and lawyers, and she certainly knew the terrain. Before turning her attention to the small screen, she worked as a deputy district attorney in Los Angeles for two and a half years. She quickly grew disillusioned with a revolving-door criminal justice system that seemed to her to boil down to a jousting match between opposing lawyers, with little regard for guilt or innocence. In a 1986 interview with The San Francisco Examiner, she recalled being handed an almost certain victory in an otherwise weak case involving a knife killing because of an oversight by the defense: 'I felt really challenged, and my adrenaline was pumping. I realized I could win this case. And I slept on it. I went, 'My God, has winning become more important than justice?'' Her unflinching view of the system informed her tenure in television. In 1983, she began writing for 'Cagney & Lacey,' bringing depth and realism to a CBS series that shook up the traditional knuckles-and-nightsticks cop-show genre by focusing on two female New York City police detectives, Christine Cagney (Sharon Gless) and Mary Beth Lacey (Tyne Daly). Want all of The Times? Subscribe.
Globe and Mail
18-06-2025
- Business
- Globe and Mail
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ('Eyenovia' or the 'Company'), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capital strategy. Avenue Capital Group, now the Company's largest common stockholder, has agreed to amend Eyenovia's senior secured debt to further support the Company as it builds its HYPE treasury and reserve of the HYPE token. Pursuant to the terms of the amendment, the maturity date of the debt has been extended from November 1, 2025 to July 1, 2028 and its interest rate reduced from 12% to 8%. One half of the interest will be paid monthly in cash with the other half accrued and paid upon maturity. The Company will make interest-only payments during the initial 18 months of the extended term with equal principal and interest payments for the remaining 18 months. Michael Rowe, Chief Executive Officer of Eyenovia, stated, 'We are very grateful to Avenue Capital Group for their significant commitment and support of our innovative treasury strategy. We are pleased that they are positioned as a long-term partner, and we look forward to generating the sustained value creation that we anticipate from this initiative as well as the continued development and potential commercialization of our novel Optejet dispensing platform for the benefit of all shareholders.' Strategic Advisor Appointed for HYPE Treasury Strategy To support the Company's growing presence in the digital asset space, Eyenovia is also pleased to announce the appointment of Max Fiege as Strategic Advisor to support the HYPE Treasury strategy. He will support stakeholder education, ecosystem advocacy, treasury architecture, and risk oversight. Mr. Fiege currently serves as Principal at Merenti Capital GmbH, deploying proprietary capital across liquid and early-stage digital asset opportunities. With a background in blockchain growth and a track record of investing in innovative crypto projects, Mr. Fiege is well recognized for his expertise in navigating and shaping the digital finance landscape. 'It is a privilege to advise Eyenovia on the productive deployment of its HYPE treasury and I look forward to delegating Merenti Capital's own HYPE balance sheet to the Company's validator. Together, we will push the HYPE ecosystem forward,' said Mr. Fiege, Principal at Merenti Capital. 'Arguably no blockchain network has matched Hyperliquid's achievement: friction-free, transparent trading secured entirely on-chain. It is rare that a native token's incentives truly track the network's success. I believe HYPE is the best positioned digital asset for the future and that Eyenovia will effectively capture that value for shareholders.' About the HYPE Token HYPE is the native token of the Hyperliquid layer one blockchain (L1). HYPE is staked by, or delegated to, validators participating in the network's custom consensus algorithm, HyperBFT, which is optimized for order book logic and allows users to trade spot and futures markets in a non-custodial, on-chain fashion. Staked HYPE unlocks further utility in the form of trading fee discounts, with referral bonuses and builder-deployed markets (HIP-3) to be introduced in the future. Circulating HYPE is autonomously bought back and sequestered with trading fees accrued on the network's enshrined markets. As of June 2025, HYPE has become the 12th-largest cryptocurrency by market capitalization. About Eyenovia, Inc. Eyenovia, Inc. is a pioneering digital ophthalmic technology company and the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE. With this dual focus, Eyenovia continues to revolutionize topical eye treatment while providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility. Eyenovia is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. For more information, please visit Forward Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our platform technology, the viability of, and risks associated with, our new cryptocurrency treasury strategy, the clinical trials that may be necessary in connection with the clearance of the Optejet UFD, the timing for sales growth of our approved products. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds to maintain our business operations and to make payments on our debt obligations as and when necessary. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Associated Press
04-06-2025
- Business
- Associated Press
Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Jun 4, 2025-- Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the first quarter ended March 31, 2025 and issued short and long-term financial guidance. Recent Highlights 'We are pleased that our lender and the new and existing investors who participated in the private placement have recognized the meaningful success we have achieved in restructuring the business and increasing revenue while significantly reducing operating expenses and free cash flow burn, as demonstrated in our first quarter 2025 financial and operational results,' said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'We have significantly improved the liquidity profile of the Company, and we expect to deliver additional gross margin expansion and further reductions in operating losses and free cash flow burn in 2025. We remain steadfastly committed to operational excellence and to position Sonendo for robust, long-term and profitable growth.' As of March 31, 2025, the Company's cash, cash equivalents and short-term investments totaled $7.2 million, which does not include the $4.7 million in estimated net proceeds the Company received in the private placement, and there was $14.2 million of principal outstanding under its credit facility. Financial Guidance The Company is providing the following short and long-term financial guidance, which reflects management's latest expectations. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's expectations regarding short- and long-term financial performance, including (among other things) GAAP gross margin, adjusted EBITDA and free cash flow; the Company's expectations to deliver additional gross margin expansion and further reduce operating losses and free cash flow burn in 2025; and the Company's ability to achieve robust, long-term and profitable growth. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. View source version on CONTACT: Investor Contact: [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH DENTAL MEDICAL DEVICES SOURCE: Sonendo Copyright Business Wire 2025. PUB: 06/04/2025 06:30 AM/DISC: 06/04/2025 06:29 AM
Associated Press
22-05-2025
- Business
- Associated Press
WIN SOURCE Ranked 13th on Supply Chain Connect's 2025 Top 50 Global Electronics Distributors List
LAGUNA HILLS, Calif., May 22, 2025 /PRNewswire/ -- WIN SOURCE, a global independent distributor of electronic components, has been ranked 13th on the 2025 Top 50 Global Electronics Distributors List released by Supply Chain Connect. The ranking comprehensively evaluates distributors based on global revenue scale, operational infrastructure, regional coverage, and channel influence. It has become a key benchmark within the electronics distribution sector. WIN SOURCE's inclusion among the top positions reflects the company's sustained operational capabilities and growing influence across major global markets. 'The real challenge in distribution lies not in the act of distribution itself, but in the ability to consistently deliver certainty amid uncertainty,' said Ethan, CEO of WIN SOURCE. 'We remain focused on fulfillment systems, digital transparency, and regional responsiveness, staying committed to long-term, sustainable development rather than reacting to short-term fluctuations.' In recent years, WIN SOURCE has expanded its fulfillment capabilities across North America, Europe, and Asia-Pacific. By leveraging a multi-regional network and centralized platform management, the company has improved delivery responsiveness and inventory visibility on a global scale. As market volatility and sourcing complexity continue to increase, performance metrics for distributors now emphasize not only geographic coverage, but also regulatory reliability, supply continuity, and transparency across distribution processes. About WIN SOURCE WIN SOURCE is a leading electronic components supplier, offering innovative procurement solutions that ensure rapid access to real-time product insights and seamless support for customers worldwide. With a mission to redefine exceptional customer service, WIN SOURCE combines advanced e-procurement systems with a customer first approach to eliminate delays and simplify global sourcing challenges. For further information, contact: Phone:+65 6865 9377 Email: [email protected] Website: Company Address: 23046 Avenida de la Carlota, Laguna Hills, CA 92653, United States Reprinted from WIN SOURCE ELECTRONIC-NEWS © 2025 Win Source Electronics. All rights reserved. This content is protected by copyright and may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Win Source Electronics. View original content: SOURCE WIN SOURCE
